Category Archives: Immunology

Images from the strangest graduation day in UCC history; Medical students prepare to go ‘into the trenches’ – Echo Live

Almost 200 UCC medical graduates are set to head "directly into the trenches" in the battle against Covid-19, as they graduated in an unconventional ceremony today.

It was an unprecedented event, which saw a total of 197 graduates conferred - the first in UCCs 175-year history to be conducted entirely online.

Taoiseach Leo Vardakar, one of the keynote speakers at the graduation, said that for the first time in Ireland, every graduate of medicine will be offered an internship within the health system as part of the effort to battle the Covid-19 pandemic.

Mr Varadkar made the pledge as he addressed the University College Cork Medicine graduates of 2020 - whose exams and graduation were brought forward to get more doctors into the field amid the pandemic.

"I know we're living in very strange times as a pandemic affects the world," Mr Varadkar said in a pre-recorded message.

"You're graduating early, and you're doing so without being able to celebrate with your friends and your families as I know you'd like to.

"But there will be a time for that in the months ahead, when we develop new treatments, a new vaccine, a much better and more effective testing and contact tracing regime.

"In the meantime, we need you to graduate early and to start work as interns already, because there's so much work to be done.

"I know you will be starting in posts in the middle of May, in hospitals, and also some of you in community settings, and for the first time ever, we are providing for over 1,000 internships for medical graduates in Ireland.

"That pretty much means that everyone graduating this year will be offered an internship," he said.

Across the city and county, graduates, their friends and relatives, tuned in online to watch the unique conferring.

For Robert Shannon, son of Fianna Fil councillor Terry Shannon, the occasion was indeed a "pretty bizarre" affair.

He watched the proceedings along with his housemate, Kathryn Lesko, who also conferred today.

Dr Shannon, who also has a BSc in Neuroscience from UCC and an MSc in Immunology and Global Health from Maynooth University, said it was a graduation like no other.

"It was a bit of a change from the usual pageantry of conferrings," he laughed.

"It was pretty bizarre alright and a small bit of an anticlimax after all the work but I think it's a testament to the class group that almost 200 of us made it out the other side when the exams were brought forward," he said.

The graduates are set to begin their posts from May 25, joining the frontline in the battle against Covid-19.

Dr Shannon says he is used to working in hospital environments but the daunting prospect is entering into his preferred area, infectious diseases - heading "directly into the trenches".

Also graduating today was Kate Henry from Ballincollig, who received a first-class honours degree in Medicine.

Dr Henry is a third-generation UCC medical graduate, who will be starting work as an intern in the Southern Intern Training Network (UCC) in May.

Speaking at the conferrings today, UCC President Patrick O'Shea commended the resilience of the graduates.

"Your resilience and adaptability in responding to Covid-19 is genuinely remarkable and has no doubt prepared you for the challenges and rewards of the career path you have chosen.

"I wish you every success in your careers. We are all deeply proud of your accomplishments.

"What you have achieved in 2020, and indeed this event itself will constitute an essential chapter in the history of your University, your Alma Mater, University College Cork," he said.

Link:
Images from the strangest graduation day in UCC history; Medical students prepare to go 'into the trenches' - Echo Live

What it means to be immune to the coronavirus – Mashable SE Asia

The coronavirus is a vexing parasite.

Around one in four infected people may have no symptoms, as far as experts currently know (the disease is new, so these numbers aren't yet fully certain). So it leaves many of us with a burning question: Is it possible you were infected, but didn't get sick?

It's a question of paramount importance. A bedrock of immunology (the study of how the body defends against infections) is if a virus infects you and you fight off the infection you develop an immunity to it for some time, even if you had mild symptoms. This means, after you eventually get a blood test to show immunity, you could then safely reenter society without immediately catching and spreading the respiratory disease COVID-19.

"The golden rule of immunology is if you are infected with a virus, get sick, and recover, you probably won't get reinfected with the same virus," said Mark Cameron, an immunologist at Case Western Reserve University who previously helped contain the outbreak of another deadly coronavirus, SARS, in 2003.

When exposed to a new virus, the body will soon create defensive proteins in your bloodstream, called antibodies, that block the virus from successfully hijacking the body's cells in the future. (That's why vaccines which encourage your body to make antibodies work, and the U.S. eradicated polio over 30 years ago).

This is happening with the new coronavirus, too, but disease experts must observe the response of recovered coronavirus patients to understand how effective this immunity is, how long it will last, and if some people can be reinfected. The CDC, for example, just started recruiting Americans to see who has been infected and made antibodies. People infected with SARS developed immunity for an average of two to three years.

"It's very likely if you got exposed that you mounted a response and you would have antibodies," explained Dr. Vince Silenzio, an M.D. and professor at the Rutgers School of Public Health. "We are fairly certain people are becoming immune [to the new coronavirus]."

And critically, just because someone had a mild response or showed no symptoms at all there's no conclusive evidence they build up a weaker immune defense against the coronavirus, officially named SARS-CoV-2.

"The bottom line is it's not necessarily true yet that people with mild infections have less of an immune response," said Silenzio.

"Asymptomatic infections are just as likely to grant immunity to the bearer as frank infections [meaning infections that cause disease], despite the challenge in identifying these infections and the risk of spread they entail," agreed Cameron.

Why, though, might a significant number of people have such mild (or no) symptoms to this new coronavirus? There could be genetic or health differences that make it more difficult for the coronaviruses to infect a cell. It's also possible that people with milder infections were only exposed to a tiny amount of the virus (like someone picking up just a few particles off a piece of mail versus an ER doctor getting sprayed with millions of viral particles). "It's possible that asymptomatic people were exposed to a much lower dose," said Brian Baker, a biochemist at the University of Notre Dame.

The reason there are severe, mild, and asymptomatic infections will be intensively researched throughout this year, and beyond. Although researchers have learned a great amount about this microbe, the virus is still new to science. After all, this coronavirus only spilled over to humans from other animal species in the last five months. "We dont have all the answers yet," Silenzio said. "But on the other hand," he added, "it's amazing we have as many answers as we do."

As far as peoples' future immunity is concerned, there are still some weighty questions out there. For example, there are recent reports out of South Korea and China of people who supposedly already had coronavirus, but then tested positive for the infection again. This would challenge the idea they developed immunity. "There is some controversy currently regarding whether people are truly immune to COVID-19 once they have it, because there have been stories to the contrary," said Cameron.

"This virus is teaching us new stories"

There's an explanation, however, for these reinfections. There's evidence the virus may have temporarily eased off in these patients, and later picked up steam again. So it could have been the same infection all along not someone getting sick from a new infection. "Infection causes different courses of disease in people that's not unusual," explained Cameron.

Another looming question is how long immunity to the new coronavirus may last, either after recovering from an infection or getting a vaccine (when one becomes available in 2021 at the earliest). For example, if the coronavirus mutates too much, the body's immunity is lost. "Some viruses change rapidly and some don't change rapidly," said Notre Dame's Baker.

The polio virus, for example, doesn't mutate quickly. So a polio vaccination (which sparks the body to produce new antibodies) generally lasts one's entire life. But other viruses, like influenza, mutate constantly and require those annual flu shots you're so familiar with.

The good news is the new coronavirus hasn't been mutating quickly so far, explained Baker. This means it's relatively stable. We don't know how long immunity might last, but this virus is unlikely to change so fast it will reinfect people or outpace forthcoming vaccines, said Cameron.

At the end of the day, this coronavirus may unwittingly help humanity tame the pandemic. While it's true that asymptomatic people can spread the virus when they're infected (that's why everyone must social distance right now), if one in four infected people are truly asymptomatic, that means that likely millions of people will ultimately develop immunity whether they know it or not and won't be able to spread the virus around until we get a vaccine. "That would be a good thing," said Baker.

"We can count on the fact that the vast majority of COVID infections will cause immunity," said Cameron, noting that a vaccine will then only add to the number of immune people. Ultimately, this is how we end this grim pandemic, now that we've failed to contain it.

Though immunologists have an ever-strengthening grip on this coronavirus, they're aware the microbe is still revealing itself. Each day scientists around the globe learn more about how it behaves and infects people. So stay tuned for an improved understanding of how immunity will play out with SARS-CoV-2, a virus that's on pace to kill some 68,000 Americans by August (but likely many more if we don't sustain extreme social distancing measures).

"This virus is teaching us new stories," said Cameron. "The story is not yet written."

Go here to read the rest:
What it means to be immune to the coronavirus - Mashable SE Asia

What it means to be immune to coronavirus – Mashable

The coronavirus is a vexing parasite.

Around one in four infected people may have no symptoms, as far as experts currently know (the disease is new, so these numbers aren't yet fully certain). So it leaves many of us with a burning question: Is it possible you were infected, but didn't get sick?

It's a question of paramount importance. A bedrock of immunology (the study of how the body defends against infections) is if a virus infects you and you fight off the infection you develop an immunity to it for some time, even if you had mild symptoms. This means, after you eventually get a blood test to show immunity, you could then safely reenter society without immediately catching and spreading the respiratory disease COVID-19.

"The golden rule of immunology is if you are infected with a virus, get sick, and recover, you probably won't get reinfected with the same virus," said Mark Cameron, an immunologist at Case Western Reserve University who previously helped contain the outbreak of another deadly coronavirus, SARS, in 2003.

When exposed to a new virus, the body will soon create defensive proteins in your bloodstream, called antibodies, that block the virus from successfully hijacking the body's cells in the future. (That's why vaccines which encourage your body to make antibodies work, and the U.S. eradicated polio over 30 years ago).

This is happening with the new coronavirus, too, but disease experts must observe the response of recovered coronavirus patients to understand how effective this immunity is, how long it will last, and if some people can be reinfected. The CDC, for example, just started recruiting Americans to see who has been infected and made antibodies. People infected with SARS developed immunity for an average of two to three years.

"It's very likely if you got exposed that you mounted a response and you would have antibodies," explained Dr. Vince Silenzio, an M.D. and professor at the Rutgers School of Public Health. "We are fairly certain people are becoming immune [to the new coronavirus]."

And critically, just because someone had a mild response or showed no symptoms at all there's no conclusive evidence they build up a weaker immune defense against the coronavirus, officially named SARS-CoV-2.

"The bottom line is it's not necessarily true yet that people with mild infections have less of an immune response," said Silenzio.

"Asymptomatic infections are just as likely to grant immunity to the bearer as frank infections [meaning infections that cause disease], despite the challenge in identifying these infections and the risk of spread they entail," agreed Cameron.

Why, though, might a significant number of people have such mild (or no) symptoms to this new coronavirus? There could be genetic or health differences that make it more difficult for the coronaviruses to infect a cell. It's also possible that people with milder infections were only exposed to a tiny amount of the virus (like someone picking up just a few particles off a piece of mail versus an ER doctor getting sprayed with millions of viral particles). "It's possible that asymptomatic people were exposed to a much lower dose," said Brian Baker, a biochemist at the University of Notre Dame.

The reason there are severe, mild, and asymptomatic infections will be intensively researched throughout this year, and beyond. Although researchers have learned a great amount about this microbe, the virus is still new to science. After all, this coronavirus only spilled over to humans from other animal species in the last five months. "We dont have all the answers yet," Silenzio said. "But on the other hand," he added, "it's amazing we have as many answers as we do."

As far as peoples' future immunity is concerned, there are still some weighty questions out there. For example, there are recent reports out of South Korea and China of people who supposedly already had coronavirus, but then tested positive for the infection again. This would challenge the idea they developed immunity. "There is some controversy currently regarding whether people are truly immune to COVID-19 once they have it, because there have been stories to the contrary," said Cameron.

"This virus is teaching us new stories"

There's an explanation, however, for these reinfections. There's evidence the virus may have temporarily eased off in these patients, and later picked up steam again. So it could have been the same infection all along not someone getting sick from a new infection. "Infection causes different courses of disease in people that's not unusual," explained Cameron.

Another looming question is how long immunity to the new coronavirus may last, either after recovering from an infection or getting a vaccine (when one becomes available in 2021 at the earliest). For example, if the coronavirus mutates too much, the body's immunity is lost. "Some viruses change rapidly and some don't change rapidly," said Notre Dame's Baker.

The polio virus, for example, doesn't mutate quickly. So a polio vaccination (which sparks the body to produce new antibodies) generally lasts one's entire life. But other viruses, like influenza, mutate constantly and require those annual flu shots you're so familiar with.

The good news is the new coronavirus hasn't been mutating quickly so far, explained Baker. This means it's relatively stable. We don't know how long immunity might last, but this virus is unlikely to change so fast it will reinfect people or outpace forthcoming vaccines, said Cameron.

At the end of the day, this coronavirus may unwittingly help humanity tame the pandemic. While it's true that asymptomatic people can spread the virus when they're infected (that's why everyone must social distance right now), if one in four infected people are truly asymptomatic, that means that likely millions of people will ultimately develop immunity whether they know it or not and won't be able to spread the virus around until we get a vaccine. "That would be a good thing," said Baker.

"We can count on the fact that the vast majority of COVID infections will cause immunity," said Cameron, noting that a vaccine will then only add to the number of immune people. Ultimately, this is how we end this grim pandemic, now that we've failed to contain it.

Though immunologists have an ever-strengthening grip on this coronavirus, they're aware the microbe is still revealing itself. Each day scientists around the globe learn more about how it behaves and infects people. So stay tuned for an improved understanding of how immunity will play out with SARS-CoV-2, a virus that's on pace to kill some 68,000 Americans by August (but likely many more if we don't sustain extreme social distancing measures).

"This virus is teaching us new stories," said Cameron. "The story is not yet written."

See the original post:
What it means to be immune to coronavirus - Mashable

Temple researchers receive NIAID grant to study immunological synapse formation – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Apr 14 2020

Switching immune cells on is a critical step in combating infection. In the case of T cells, which are key players in immunity, this happens when dormant T cells circulating in the blood encounter a suspicious agent on the surface of specialized antigen-presenting cells (APCs). APCs detect and pick up foreign agents they encounter as part of routine immune surveillance.

In order for T cells to get a good read on foreign molecules, they must establish a close communication interface with APCs. This interface, known as an immunological synapse, is vital to T-cell activation. Researchers have been doggedly pursuing a greater understanding of what happens during synapse formation and how these events shape immune responses against everything from the common cold to novel infections to cancer.

Now, thanks to a new $1.98M grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID), scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) are poised to make major headway into the study of immunological synapse formation.

T-cell activation is vital for immunity, for fighting off infectious diseases. We're living through a pandemic right now, and COVID-19 is showing us why it is so important to develop a deeper knowledge of the mechanisms underlying T-cell activation."

Jonathan Soboloff, PhD, Professor of Medical Genetics and Molecular Biochemistry at the Fels Institute for Cancer Research and Molecular Biology at LKSOM, and senior investigator on the new grant

A major goal of the research funded by the new NIAID award is to identify the role in immunological synapse formation of a molecule known as STIM1. STIM1 is a calcium sensor located within the endoplasmic reticulum, a continuous membrane system in the cell that functions in part in protein folding and transport. In previously published work within the field, STIM1 was shown to move to the side of the T cell where the immunological synapse forms. Dr. Soboloff and colleagues have found that STIM1 localization to the immunological synapse raises local calcium levels, leading to the loading of calcium into mitochondria - the energy-supplying powerhouses of cells.

These observations suggest that STIM1 supports mitochondrial function during T-cell activation. "Using novel STIM1 mutants, we will determine what makes STIM1 move to the immunological synapse during T cell activation," Dr. Soboloff said. "This will also allow us to characterize its impact on cellular metabolism to better define how STIM1 and calcium regulation impact T-cell activation."

Under the new grant, Dr. Soboloff also plans to investigate the role of proteins known as septins in immunological synapse formation and the activation of immune cells. Septins provide a sort of scaffolding inside cells that influences protein movement to specific locations and that creates barriers to prevent proteins from leaving cellular compartments. While septins are known to contribute to STIM1 function in some contexts, there are no publications regarding their involvement in protein localization during the formation of the immunological synapse.

"Ultimately, through experiments in cell lines and mouse models, we want to identify the underlying molecular mechanisms driving STIM1 translocation and determine the physiological relevance of this process," Dr Soboloff explained. "In addition to extending our understanding of STIM1 in the context of T-cell activation, new knowledge of how these mechanisms are applied could lead to novel insight into the significance of STIM1 regulation in cellular metabolism and its implications more generally in cell biology."

The NIAID award provides support for Dr. Soboloff's research into STIM1 and T-cell activation through March 2025. Co-investigators on the award include Yi Zhang, MD, PhD, Professor of Microbiology and Immunology at the Fels Institute for Cancer Research and Molecular Biology, and John Elrod, PhD, Associate Professor of Pharmacology and Associate Professor at the Center for Translational Medicine and the Alzheimer's Center at Temple.

Follow this link:
Temple researchers receive NIAID grant to study immunological synapse formation - News-Medical.Net

Study looks at chance of social distancing continuing through 2022 – MyNorthwest.com

A sign posted at a Seattle Costco warehouse. (MyNorthwest photo)

A new study looks to understand the future of how COVID-19 will spread in the postpandemic period, and just how long well need social distancing measures.

The study, authored by five researchers fromthe Department of Immunology and Infectious Diseases and the Department of Epidemiology at Harvards School of Public Health, was published on ScienceMag.org on Tuesday.

Research paper claims social distancing needed for 18 months or more

The various models implemented by the study present a range of possible outcomes, including a scenario where the outbreak completely ends in 2022, with some social distancing measures relaxed by early-to-mid-2021.

An improved outlook will be largely dependent on new therapeutics, vaccines, or other interventions such as contact tracing and quarantine.

In the absence of such interventions, surveillance and intermittent distancing may need to be maintained into 2022, it estimates.

That being so, the study also points out that any social distancing measures extending into 2022 present a substantial social and economic burden. It lists a handful of urgent priorities well need to focus on if were to avoid that future.

That includes:

The study also looks into how the virus might spread seasonally in the months and years ahead, predicting that we could very well see regularly recurring winter outbreaks. Additionally, even after the pandemic is completely under control this year, it warns that we could see a resurgence as late as 2024.

While it acknowledges that SARS the closest genetic relative to coronavirus was largely eradicated by intensive public health measures, most public health officials consider this scenario unlikely.

State Superintendent says school closures likely to fall and beyond

Alternatively, the transmission of (COVID-19) could resemble that of pandemic influenza by circulating seasonally after causing an initial global wave of infection, the study concludes.

The study closes by noting that its goal is less to endorse social distancing measures years into the future, and more to identify likely trajectories of the epidemic under alternative approaches and to spur innovative ideas to expand the list of options to bring the pandemic under long-term control.

See the original post here:
Study looks at chance of social distancing continuing through 2022 - MyNorthwest.com

Disease Research Leads in Colorado – AG INFORMATION NETWORK OF THE WEST – AGInfo Ag Information Network Of The West

Scientists around the world are racing to find a vaccine or treatment that will hinder the coronavirus harmless, each taking a unique trajectory.

In Colorado top agriculture and animal research is leading the way toward potential breakthroughs. Colorado State University VP for Research Alan Rudolph.

We study the immunological profile of the virus and the host or host response in animals to better understand the immunological profile and try to translate that to humans. There is research on immunology in animals that were doing. The other thing that the animal community is aware of is that alpacas are used to create thermostable antibodies for use in the current Covid response. In fact were doing that research at CSU on alpacas to explore whether they can produce stable antibodies against disease. There are other groups looking at how to create smiliare types of reagents that could be used in the Covid response using the immunological response from animals.

Nearby CSU engineers and infectious disease researchers have been developing a low-cost sprayable disinfectant that kills the virus that causes COVID-19 and that can be brought to market quickly working with a design firm in Ft. Collins. The technology deactivates the virus by rendering it incapable of replicating. Local researchers are using similar technology to develop a vaccine for the disease.

Dr. Rudolph says CSUs Infections Disease Research and Response Program is allowing researchers to quickly take their ideas and put them into practice.

Read more from the original source:
Disease Research Leads in Colorado - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West

Tumors hijack the cell death pathway to live – Newswise

Newswise DALLAS April 13, 2020 Cancer cells avoid an immune system attack after radiation by commandeering a cell signaling pathway that helps dying cells avoid triggering an immune response, a new study led by UTSW scientists suggests. The findings, published in a recent issue ofNature Immunology, could eventually lead to new ways to augment existing treatments to fight this disease.

Researchers have long known that radiation a mainstay of treatment protocols for many types of cancerous tumors kills cancer cells in two different ways: The high-energy beams smite some cells directly, and these dead cells leak DNA that triggers a tumor-fighting immune response through proteins known as interferons (IFNs). But even though cancerous cells make up the vast majority of a tumor, explains study leaderYang-Xin Fu, Ph.D., studies have shown that these cells secrete very little IFN themselves, muting the immune response that could eradicate them.

We figured that tumor cells must have some mechanism to escape interferon production, Fu says.

To figure out what that mechanism might be, he and his colleagues tested 42 FDA-approved drugs that block various parts of cell signaling on mouse colon cancer cells growing in petri dishes, searching for any that might be able to prompt these cells to secrete abundant interferons after radiation. Their search identified a drug known as emricasan, often prescribed to liver transplant recipients to help prevent rejection. This drug broadly inhibits production of a family of enzymes known as caspases, which not only help trigger cell death but also muffle the immune systems response to dying cells.

Further experiments indicated that one particular member of this family known as caspase-9 (CASP9) was key for preventing the cancer cells from secreting IFN. When the researchers genetically manipulated cancer cells to turn off CASP9 production, radiation increased their IFN production thousands-fold compared with wild type cancer cells that hadnt been modified.

When the researchers placed these CASP9-deficient cancer cells into mice, their tumors completely regressed after radiation, compared with those carrying tumors made of wild type cells. Additional experiments showed that a particular population of immune cells, known as CD8+T cells, were recruited by the secreted interferon and were responsible for this dramatic regression.

Peering deeper into the mechanism behind how CASP9 helps protect tumor cells from the immune system, the researchers looked for the molecular trigger behind the production of this enzyme. Because cells secrete DNA from the nucleus only after theyre dead, the researchers looked to an event that occurs earlier after radiation damage: the secretion of DNA from mitochondria, the cells power-generating organelles. When the researchers removed mitochondrial DNA from cancer cells, they no longer produced IFN when they were irradiated, suggesting that this was the triggering event.

Although blocking CASP9 production appears to be a promising way to boost the anti-tumor immune response, it comes with a significant drawback: When tumors in animal models lost CASP9 signaling, these masses found a new way to evade immune attack by stepping up production of a protein called programmed death-ligand 1 (PD-L1), which shields cancer cells from immune discovery. However, when the researchers administered an antibody that blocked PD-L1, the tumors regressed again. Using a combination of CASP9 inhibitors with anti-PD-L1 could offer a new strategy for boosting the effects of radiation, Fu says.

This approach could eventually give doctors the confidence that theyre irradiating the tumor that they can see and using the immune system to knock out other tumor cells that they cant see, he adds. Together, this may be able to give some patients long-lasting survival thats not yet achievable.

Other UTSW researchers who contributed to this study include Chuanhui Han, Zhida Liu, Yunjia Zhang, Aijun Shen, Chunbo Dong, Anli Zhang, Casey Moore, Zhenhua Ren, Changzheng Lu, Xuezhi Cao, Chun-Li Zhang, and Jian Qiao.

This study was supported by Texas CPRIT grants RR150072 and RR180725.

Dr. Fu holds the Mary Nell and Ralph B. Rogers Professor in Immunology.

About UTSouthwestern Medical Center

UTSouthwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 22 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.

Excerpt from:
Tumors hijack the cell death pathway to live - Newswise

Back story: Profiling the scientists who’ve entered the fray against COVID-19 – The San Diego Union-Tribune

Health care workers are rightfully getting a lot of attention for battling the coronavirus. But theres a second front in the war against the virus: science.

As one of the largest science centers in the U.S., San Diego is playing an especially crucial role that involves everything from tracking COVID-19 to the search for a vaccine.

In todays InDepth, the Union-Tribune highlights the work of local researchers and has them describe the moment they realized how bad things might get. Reporter Gary Robbins explains how the story came together.

Q: Did something in particular trigger this story?

A: Ive been very moved by watching Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases. He has been clearly and calmly explaining the threat posed by COVID-19 and how scientists are responding. There are a lot of scientists like him here, so I turned the spotlight their way.

Q: In what ways are they like him?

A: Theyre tireless, committed and circumspect. A lot of local laboratories are closed to help slow the spread of the virus. Many scientists have set up shop in their living rooms or dens. Some of them answered my emails in the middle of the night or when they could have been spending time with their families. They werent seeking publicity. They were trying to keep people informed. And they werent making outlandish claims.

Q: Did they speak as clearly as Fauci?

A: Unfortunately, few people do. Thats especially true in science where theres a cultural imperative to quantify things to the Nth degree. But with a little coaxing, most people get to the point.

I wasnt sure how far to press scientists. Like the rest of us, they are exhausted and nervous. One researcher said that if a member of his family gets COVID-19 it will be because he unknowingly brought it home. Another told me he was preparing to take his son, who has stage IV cancer, to the hospital for chemotherapy and was worried that he might become infected with COVID-19. We were strangers, and in a nano-second I was speechless.

Q: Have you been able to interview scientists in person?

A: Not for the past couple of weeks, and that only makes sense. But it makes reporting harder. The key to a lot of interviews is being able to read a persons face and body language. It isnt easy to do that over Skype. People look washed out and the audio sounds like your mic was dropped in a fish tank. This is also a drag because I simply like talking to people in person.

Q: Was there a moment that could be described as powerful?

A: Yes. It involved Erica Ollmann Saphire, a virus fighter at the La Jolla Institute. Shes a warm, funny person and a gifted speaker. I asked her if she experienced a gut check moment when she realized how bad things might get. She gave an eloquent response in which she ended by describing COVID-19 as being like a wall of water coming at you, a tsunami. Were going to have to build a ship to get out of it.

Ive learned to stay quiet when people are talking like this. Theyll often deliver a bit more. She did, saying, We must deal with this. We cannot fail.

It was like listening to Churchill implore the British to remain strong when London was being bombed by the Germans during World War II.

The next day, she wanted to tone down her comment a bit. I asked her not to. Much of the public thinks of scientists as unknowable nerds in white lab coats. The opposite is true. And were experiencing an extraordinary moment in which much of the public is listening to scientists.

Fortunately, Saphire cut me some slack on this.

Q: The Union-Tribune recently lost its biotech reporter, Bradley Fikes. Has it been difficult covering the pandemic and response without him?

A: Yes. I miss Bradley. He passed away in November of a heart attack. He had an encyclopedic knowledge of immunology and viruses something that made him a beloved and respected figure among scientists. I could always wave at him and say, Remind me again of the difference between enzymes and proteins. Ive forgotten. When it came to the life sciences, he was a flesh-and-bone version of Google.

Bradley would have greatly enriched our coverage of the coronavirus.

There is a piece of good news to report. Jonathan Wosen, the Union-Tribunes new biotech reporter, begins work on Monday. He earned a doctorate in immunology at Stanford. Like Bradley, hes wicked smart.

Follow this link:
Back story: Profiling the scientists who've entered the fray against COVID-19 - The San Diego Union-Tribune

With no US plan to return to normal, some states are creating their own – Walla Walla Union-Bulletin

America doesnt have a plan to return to normal. The federal governments failure to produce one could leave millions of workers, students and families stuck inside even after hospitals and first responders have weathered the initial crisis.

Reopening society, experts say, will require the regular testing of millions of people, a reliable and fast nationwide reporting network and an army of thousands of investigators tasked with tracking down those who may have been exposed to the virus. Experts have compared this to the effort to put a man on the moon and the Manhattan Project.

The federal government has yet to produce even the framework of a plan let alone the supplies and workforce to carry it out leaving states and local governments to cobble together their own tenuous road maps.

It really does need to be started by the federal government, said Gigi Gronvall, an immunology specialist at the Johns Hopkins Center for Health Security. Its not something that you can just throw together. It should be worked on now while the tests are coming online and not weeks and weeks down the road.

When the health emergency does abate, governors will face political pressure to loosen restrictions on business, travel and socializing. But experts say doing so without a widespread testing system only invites a second outbreak.

The move toward less restrictive physical distancing could precipitate another period of acceleration in case counts, reads a road map written by several public health experts, including former U.S. Food and Drug Administration Commissioner Scott Gottlieb, which calls for careful surveillance before lockdowns are lifted. The report was published independently by the American Enterprise Institute, the right-leaning Washington, D.C., think tank where Gottlieb is a resident fellow.

The 16-page report drafted by Gottlieb and others is the most prominent plan for societys return to normal. It calls for a comprehensive national sentinel surveillance system. But state officials say the U.S. government has proven inept, and theyre forging ahead with their own plans instead of waiting for its playbook. Whether those plans prove viable without real federal support is an unanswered question.

With a strong federal presence, we could be so much further forward in terms of our public health response, said San Francisco Assessor Carmen Chu, who serves on the task force planning the citys recovery. The lack of leadership at the federal level has hurt us. We really cant do it alone.

Even if the health care crisis evaporated overnight, not one state currently has a sufficient testing and tracing system to begin easing restrictions, according to another report on testing from Gottlieb and others.

(Reopening society) is going to come down to how good we are with testing, New York Gov. Andrew Cuomo, a Democrat, said in a news conference last week. You have 19 million people in the state of New York. Just think of how many people you would need to be able to test and test quickly.

Cuomo said ramping up testing to the necessary scale will be an enormous effort, and hes working with the Democratic governors of New Jersey and Connecticut to coordinate a regional plan.

Theres no consensus on just how many tests will be needed nationwide to reopen the economy, but its clear the current system which is generally only testing symptomatic patients who are high-risk or work on the front lines is far from adequate.

James Bullard, president of the St. Louis Federal Reserve, said on Face the Nation that the solution is a universal testing system, an ambitious proposal that would require hundreds of millions of tests a day.

What you want is every single person to get tested every day, Bullard said. And then they would wear a badge like they would after they voted or something like that to show that theyve been tested. This would immediately sort out whos been infected and who hasnt been infected.

Bullard did not respond to questions about how his proposal would be carried out.

Utahs recovery effort is being overseen by Salt Lake Chamber President and CEO Derek Miller, who chairs the task force appointed by Gov. Gary Herbert, a Republican. The plan drafted by Millers team says that testing must become mainstream before most residents can return to work.

In order to open up businesses, we need to get to a place where we can actually do testing on-site, Miller said. Opening up segments of our economy will necessitate a significant ramp-up of mobile testing, antibody testing and asymptomatic testing. We cant flatten the curve, pat ourselves on the back and then risk a second wave.

Utah is currently testing 3,000 to 4,000 people a day, Miller said, with plans to increase to 7,000. But any plan to begin rolling back Herberts Stay Safe, Stay Home order will have to include much more testing than that.

Utah has a population of 3 million, and some workers may need regular testing to ensure they havent caught the virus. As more testing is rolled out, restrictions likely will be pulled back gradually.

I do see a phased approach to bringing segments of the economy fully back online by industry and by geography, Miller said. Experts say its uncertain what free and clear will look like in deciding whos ready to bypass social distancing and other precautions.

Other states are thinking ahead too. Cuomo has chosen a trio of business leaders to plan New Yorks rebound. Cuomos office and planners did not respond to Stateline requests for comment.

Meanwhile, Florida Chamber of Commerce President Mark Wilson said in a release that his team is already developing Floridas statewide plan to restart our economy. A month ago, March 11, just two days before President Donald Trump declared a national emergency, Wilson boasted that Florida is open for business, for travel and for spring break.

Wilson did not respond to questions about his role in state recovery planning.

A few plans already have been drafted. The Economic Research Organization at the University of Hawaii released a brief this month for restarting that states economy.

The step thats the most problematic is (developing) a well-defined system of testing, contact tracing and isolation, said Sumner La Croix, a research fellow at the organization and one of the reports authors. Right now, we know very little about how that all proceeds at the state level.

Hawaii has advantages, La Croix said, because of its geographical isolation, a relatively low number of cases so far and an already robust testing program. But officials will need to build a statewide system, perhaps by the end of the month, that brings public and private entities into a single testing regime.

If we can work on that over the next few weeks and months, I think we might be able to open up our economy here faster than some other places, he said. We could have the surveillance testing in place to relax some of the stay-at-home orders we have.

Unlike other states, Hawaii which has nearly eliminated visitor arrivals to the islands will be able to reopen without worrying that a surge of cases in a neighboring state might set back its own efforts.

Even robust testing might not be enough to return to normal. Health experts have called for an aggressive program of contact tracing to complement testing. Massachusetts is seeking to hire and train a team of 1,000 workers to attempt to track down every person whos been in contact with a confirmed coronavirus patient and instruct them to self-quarantine.

Gottliebs report states that the contact tracing necessary to keep the virus in check when society reopens will require a substantial surge in the health care workforce. So far, Massachusetts is the only state seeking to conduct widespread contact tracing. A nationwide system at the same level would require nearly 50,000 workers.

A spokeswoman for GOP Gov. Charlie Baker, who has touted the plan, declined comment.

Utahs Miller said the state is contacting about five people for every confirmed patient, a manageable number, but that the state may need to ramp up its contact tracing program if the caseload becomes overwhelming.

A pair of local governments are pioneering some of the first widespread testing programs thanks to rare partnerships with local medical companies that have stepped forward even as most states limit their tests to at-risk residents and symptomatic frontline workers.

Even those early successes show the limits of a patchwork system.

In Colorados San Miguel County, officials are partnering with a local company to offer testing to the countys 8,000 residents. United Biomedical Inc. offered free blood tests to the county that detect antibodies, showing whether someone was exposed to the virus and had immunity.

Experts and officials think these tests, known as serology tests, could be crucial to putting some people back to work, as people with immunity could safely take on frontline duties. Germany is planning to issue immunity certificates that will allow those who have recovered to ignore lockdown rules.

Even as the Colorado county collects results, Gronvall, the immunology expert, said a strong nationwide program is crucial for immunity testing. Without a regulated system, theres potential for employers to seek workers private medical information, and an incentive for people who want to go back to work to deliberately catch the virus.

Its definitely something that requires government attention, because of the potential for misuse, she said.

About 6,000 San Miguel County residents have been tested so far, with most of the results still pending. Eight residents have tested positive.

We dont know how were going to use the information yet, said Democratic County Commissioner Hilary Cooper. Were just waiting for the results and then at least well have more information with which to make informed decisions.

Without a more widespread testing system, San Miguel County doesnt expect to reopen any sooner than its neighbors.

We dont live in a bubble, we live in a region surrounded by communities that were very dependent on, Cooper said. In order for this to be highly effective, we should do it in the entire region.

Still, Cooper said the program could be instructive for other governments, noting that it took a logistical miracle just to organize testing in one small county. Although most county residents have been tested, results are slow to come in and a second round of testing was suspended, as the partner companys New York laboratory is overwhelmed.

Meanwhile, the city of Carmel, Ind., has begun testing all municipal employees for active infections. The Indianapolis suburb plans to test staff who interact with the public weekly, quarantining those who test positive. If the program proves successful, it could provide a model for how the workforce at large could get back to business with regular testing.

Of the nearly 400 tests that have been conducted so far, eight employees have tested positive, including several first responders.

The people on the front lines, if we can determine who has it, we can keep them from spreading it and protect them and their families, said GOP Carmel Mayor Jim Brainard. The more people you can detect and isolate, the less spread there will be.

Like San Miguel County, Carmel is partnering with a local medical company to offer the tests. Brainard said the testing is allowing city operations to retain some normalcy.

We want to keep providing essential city services, he said. We have to make sure our sewers run, our water runs, the garbage gets picked up. Our employees generally need to have interaction with the public, even in this period of time.

Within days, Carmel will test antibodies as well. Workers who are found to be immune will no longer be tested for active infections and will be able to donate blood to boost the immunity of others.

On Thursday, Brainard announced that Carmel would collaborate with local companies to donate 50,000 federally approved COVID-19 test kits to New York City.

(EDITORS: STORY CAN END HERE)

As states and cities make progress and continue their own planning, the lack of a federal plan has left many unknowns.

Experts and officials say even states that withstand the health care surge and create strong testing programs may find it dangerous to reopen if their neighbors fall behind, a consequence of the patchwork approach.

Rapid change has made planning difficult as well.

One month from now, the types of testing ability we have may look very different, said Chu, the San Francisco official.

Chu emphasized that the city will use an abundance of caution when deciding to reopen.

We want to make sure were not going forward one step and falling back two steps, she said.

2020 Stateline.org

Visit Stateline.org at http://www.stateline.org

Distributed by Tribune Content Agency, LLC.

PHOTO (for help with images, contact 312-222-4194): CORONAVIRUS-STATES-REOPENING

See the rest here:
With no US plan to return to normal, some states are creating their own - Walla Walla Union-Bulletin

Anti-Covid consortium in India working on therapeutic antibodies – Outlook India

Anti-Covid consortium in India working on therapeutic antibodies

New Delhi, April 12 (IANS) An anti-Covid consortium of experts with the assistance of Department of Biotechnology is working towards producing therapeutic antibodies against Covid-19.

In India, one such effort is being led by Vijay Chaudhary at the University of Delhi South Campus-Centre for Innovation in Infectious Disease Research, Education and Training (UDSC-CIIDRET), with the support of the Department of Biotechnology in the Ministry of Science and Technology.

Chaudhary''s group is isolating genes encoding antibodies, which can neutralise the SARS-CoV-2, using a large antibody library already available in-house as well as a library made from cells of patients who have recovered from COVID-19 infection.

These antibody genes will be used to produce recombinant antibodies in the laboratory, which, if successful in neutralising the virus, will become a perennial source of antibodies against this virus, both for prophylactic and therapeutic purposes.

This work is being undertaken as part of an Anti-Covid consortium under the leadership of Chaudhary and involving Amulya Panda at National Institute of Immunology and Sanjay Singh at Gennova Biopharmaceutical Limited, Pune (GBL).

Covid 19 is caused by the novel SARS coronavirus-2 (SARS-CoV-2) and it is resulting in many deaths. However, a large number of infected people are also recovering despite not having any specific treatment. This is because of antibodies produced within the body in response to the virus invasion.

Over the years, passive transfer of antibodies obtained from the plasma of convalescent patients cured of infection has been used for treatment of numerous disease conditions such as diphtheria, tetanus, rabies and ebola.

Today such therapeutic antibodies can be produced in the laboratory by DNA-based recombinant technologies. Efforts are in full swing globally to produce therapeutic antibodies against SARS-CoV-2, a statement by Department of Biotechnology said.

--IANS

san/prs

Read more here:
Anti-Covid consortium in India working on therapeutic antibodies - Outlook India